SPRY
Closed
Silverback Therapeutics Inc
15.9897
-1.4603 (-8.37%)
Last Update: 01 Jul 2025 23:01:00
Yesterday: 17.45
Day's Range: 16. - 17.4099
Send
sign up or login to leave a comment!
When Written:
5.88
Silverback Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for cancer and inflammatory diseases. The company was founded in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics' technology platform is based on its proprietary ImmunoTAC technology, which combines targeted antibodies with potent immune-stimulating payloads to selectively deliver drugs to diseased cells. The company's lead product candidate, SBT6050, is a first-in-class ImmunoTAC molecule designed to treat solid tumors.
The company has partnerships with leading pharmaceutical companies, including Bristol Myers Squibb and Genentech, to develop and commercialize its technology. Silverback Therapeutics has raised over $300 million in funding from investors including OrbiMed Advisors, Nextech Invest, and EcoR1 Capital.
The company is led by CEO Laura Shawver, who has over 30 years of experience in the biotechnology industry, including serving as CEO of Phenomix Corporation and Cleave Biosciences.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Silverback Therapeutics' technology platform is based on its proprietary ImmunoTAC technology, which combines targeted antibodies with potent immune-stimulating payloads to selectively deliver drugs to diseased cells. The company's lead product candidate, SBT6050, is a first-in-class ImmunoTAC molecule designed to treat solid tumors.
The company has partnerships with leading pharmaceutical companies, including Bristol Myers Squibb and Genentech, to develop and commercialize its technology. Silverback Therapeutics has raised over $300 million in funding from investors including OrbiMed Advisors, Nextech Invest, and EcoR1 Capital.
The company is led by CEO Laura Shawver, who has over 30 years of experience in the biotechnology industry, including serving as CEO of Phenomix Corporation and Cleave Biosciences.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








